Chikungunya Vaccine for Travelers: Ixchiq vs Vimkunya, Side Effects, Cost, and Who Needs It

If you are traveling to a region with active chikungunya transmission, you now have two FDA-approved options for a single-dose vaccine that builds protective immunity in about two weeks. Ixchiq (Valneva, approved November 2023) is a live-attenuated vaccine for adults 18 and older. Vimkunya (Bavarian Nordic, approved February 2025) is a virus-like particle vaccine for everyone 12 and older, including adults over 65. The Advisory Committee on Immunization Practices (ACIP) recommends chikungunya vaccination for most travelers heading to current outbreak zones such as Brazil, Paraguay, India, La Reunion, and parts of the Caribbean. As a physician who has treated returning travelers with chronic chikungunya arthritis, my recommendation is simple: if you are going somewhere with a recent outbreak and you are otherwise eligible, get the shot at least two weeks before you fly.

Quick facts about chikungunya vaccines

• Two FDA-approved vaccines: Ixchiq (VLA1553) and Vimkunya (PXVX0317).
• Both are single dose, administered intramuscularly.
• Immunity develops in approximately 14 days after vaccination.
• Coverage is durable. Phase 3 trials show seroprotective antibody levels persist for at least 2 to 3 years, with longer-term follow-up ongoing.
• Ages covered: Ixchiq for adults 18 and over; Vimkunya for everyone 12 and over.
• Cash price range: $300 to $475 per dose in the US travel-clinic market.
• Most US insurance plans do not cover travel vaccines. Some FSA and HSA plans will reimburse out-of-pocket costs.
• Best window to vaccinate: 4 to 6 weeks before departure; minimum 14 days.

What is chikungunya and why a vaccine matters

Chikungunya is a viral infection transmitted to humans by infected Aedes aegypti and Aedes albopictus mosquitoes, the same daytime-biting mosquitoes responsible for dengue and Zika. The hallmark symptoms are sudden high fever (often above 102°F or 39°C) and severe, often debilitating joint pain. The name itself comes from a Makonde word meaning "that which bends up," describing the stooped posture of people with acute joint pain.

According to the World Health Organization, chikungunya has been identified in more than 110 countries across the Americas, Africa, Asia, and Europe. Major outbreaks in recent years include La Reunion in the Indian Ocean (a single 2024 to 2025 epidemic involved hundreds of thousands of cases), Brazil and Paraguay (the Americas region reported nearly 300,000 chikungunya cases in 2024 alone, per the Pan American Health Organization), and the Indian subcontinent, where local transmission is ongoing in multiple states.

The disease has two phases that matter for travelers. The acute phase lasts 7 to 10 days with fever, joint pain, headache, muscle pain, rash, and fatigue. Up to 40% of patients develop a chronic phase with persistent joint pain that can last months or years. There is no specific antiviral treatment. Care is entirely supportive: rest, fluids, and analgesics. That is why a single-dose vaccine that prevents the infection in the first place is such a meaningful upgrade for the traveler tool kit.

In my emergency department, I have seen otherwise healthy travelers return from the Caribbean unable to type, walk up stairs, or lift their children for weeks. The chronic arthritis is the part nobody talks about, and it is what makes this vaccine worth the conversation.

Ixchiq vs Vimkunya: how the two chikungunya vaccines compare

Both vaccines are single-dose and approved for travel use, but they are very different products under the hood. Here is the head-to-head a traveler actually needs.

The simple way to choose between them

For most healthy adult travelers between 18 and 64 going to an active outbreak area, either vaccine is a reasonable choice. Beyond that, the picking logic is straightforward:

• Ages 12 to 17: Vimkunya only. Ixchiq is not approved.
• Ages 65 and older: Vimkunya is preferred. After several reports of serious adverse events in older adults, the FDA added a warning to Ixchiq in 2024 and ACIP refined its guidance to recommend Vimkunya for this group whenever possible.
• Immunocompromised travelers, including those on biologics, chemotherapy, or high-dose steroids: Vimkunya is preferred because it does not contain live virus.
• Pregnant or breastfeeding travelers: This is a conversation to have with a clinician. Live-attenuated Ixchiq is generally avoided in pregnancy. Vimkunya data are still emerging and most physicians defer routine use during pregnancy unless travel cannot be deferred.
• Travelers who want the longest track record: Ixchiq has been on the US market longer, with more real-world safety surveillance.

Who needs the chikungunya vaccine

Chikungunya vaccination is not routine for every international trip. It is a destination-and-activity-driven recommendation. The CDC and ACIP recommend it for the following groups.

Travelers heading to a country with an active or recent chikungunya outbreak, especially if the trip will last more than two weeks or involve outdoor activity, rural areas, or staying somewhere without window screens or air conditioning. The biggest outbreak regions in 2025 and 2026 have been:

• La Reunion (Indian Ocean) — major epidemic in 2024 to 2025 with over half a million cases reported.
• Brazil and Paraguay — the Americas region recorded more chikungunya cases in 2024 than any year on record. Northeast Brazil is the highest-risk subregion.
• India — multiple states with active transmission, especially Maharashtra, Karnataka, and Kerala.
• Caribbean — periodic outbreaks in the Dominican Republic, Cuba, Jamaica, Trinidad, and others.
• Southeast Asia — Indonesia, Thailand, Cambodia, and the Philippines have all reported clusters.
• Parts of sub-Saharan Africa, including Kenya and Ethiopia, with localized outbreaks.

Travelers with high exposure risk regardless of itinerary, including humanitarian aid workers, missionaries, researchers, and people staying with friends and family in endemic regions.

Travelers with conditions that increase the severity of chikungunya if they catch it. People with underlying joint disease, diabetes, cardiovascular disease, or chronic conditions have a higher risk of severe acute disease and prolonged joint symptoms.

Adults 65 and older going to outbreak areas are in a nuanced bucket. They have higher risk for severe chikungunya, but also a higher rate of vaccine-related adverse events with Ixchiq. Vimkunya largely solves this trade-off and is the preferred option in this age group.

If your destination has no recent chikungunya transmission and your trip is short, urban, and in good accommodations, the vaccine is not strictly necessary. A pre-trip health check is the easiest way to confirm whether your specific itinerary warrants it.

How the vaccines work

Ixchiq is a live-attenuated vaccine, meaning it contains a weakened version of the chikungunya virus. After injection, the virus replicates briefly in your body, your immune system recognizes it, and you develop antibodies. The benefit of live-attenuated technology is a strong, durable immune response from a single dose. The trade-off is that the body has to control the live virus, which is why some people experience a mild "chikungunya-like" reaction in the first week.

Vimkunya uses virus-like particle (VLP) technology. VLPs look like the chikungunya virus from the outside but contain no genetic material, so they cannot replicate or cause infection. Your immune system mounts an antibody response without ever encountering active virus. This is the same general approach used in HPV and hepatitis B vaccines and is widely regarded as one of the safest vaccine platforms available.

Both produce neutralizing antibodies in roughly 98% of recipients by day 22 to 28. Both are projected to provide multi-year protection, though long-term follow-up trials are still ongoing.

Side effects: what to actually expect

Most travelers tolerate either vaccine well. Side effects are typical of vaccinations in general, but there are some specifics worth knowing.

Common side effects of Ixchiq

In phase 3 clinical trials, the most frequently reported reactions were:

• Headache (~30%)
• Fatigue (~28%)
• Muscle pain (~24%)
• Joint pain (~17%)
• Fever (~14%)
• Tenderness at the injection site (~11%)
• Nausea (~11%)

A small subset of vaccinees (roughly 2%) experienced more pronounced flu-like symptoms reminiscent of mild chikungunya infection, usually peaking around day 3 to 7 and resolving within a week.

Common side effects of Vimkunya

In phase 3 trials, the side effect profile was generally milder:

• Headache (~22%)
• Fatigue (~21%)
• Injection site pain (~17%)
• Muscle pain (~13%)
• Joint pain (~6%)
• Fever (~3%)

Serious adverse events

In post-marketing surveillance of Ixchiq, the FDA documented a small number of serious adverse events in adults 65 and older, including several cases of severe chikungunya-like illness requiring hospitalization, and a small number of deaths in elderly recipients with multiple comorbidities. This prompted an FDA label update in 2024 and an updated ACIP recommendation to prefer Vimkunya in adults 65 and older when possible.

For Vimkunya, post-marketing data have so far been reassuring, with no equivalent serious-adverse-event signal in older adults.

If you experience high fever, severe joint pain lasting more than a few days, signs of allergic reaction (hives, swelling, difficulty breathing), or any neurological symptoms after vaccination, seek medical care and report the reaction to the Vaccine Adverse Event Reporting System (VAERS).

When to get vaccinated before your trip

Both vaccines reach protective antibody levels at approximately 14 days. That means the latest you can reasonably vaccinate is 2 weeks before departure. The ideal window is 4 to 6 weeks out, which leaves room for unexpected schedule changes, mild side effects, and stacking with other travel vaccines if needed.

Chikungunya vaccines can be administered on the same day as most other inactivated travel vaccines (typhoid Vi-PS, hepatitis A, hepatitis B, polio booster, meningococcal, rabies, Tdap, influenza). For live vaccines like yellow fever or MMR, current guidance is either same-day administration or separation by at least 28 days. A Wandr clinician will sequence your vaccines correctly during the pre-trip health check.

Chikungunya vaccine cost in the US

US travel clinics typically charge between $300 and $475 for the chikungunya vaccine, including the administration fee. Pricing varies by region, by vaccine (Vimkunya tends to run slightly higher than Ixchiq), and by clinic type. A few cost points worth knowing:

• Most commercial health insurance does not cover travel vaccines. Some employer-sponsored plans or international medical insurance riders make exceptions.
• Medicare Part B and Part D usually do not cover chikungunya vaccine for travel purposes.
• FSA and HSA accounts will typically reimburse vaccine costs as a qualified medical expense, even when commercial insurance refuses.
• Brick-and-mortar travel clinics often add a $100 to $200 consultation fee on top of the vaccine cost, plus follow-up fees if you need a second visit.

Booking online through Wandr removes the consultation overhead, so the price you see for the vaccine is the price you pay.

How Wandr handles your travel vaccines

Wandr's vaccine workflow is fundamentally different from its prescription medication workflow. For vaccines like chikungunya, you do not need a doctor's prescription. Travel vaccines are administered by pharmacists under standing orders. Here is exactly how it works:

1. Pick your destination, dates, and a partner pharmacy. Wandr matches you to a Walgreens location near your home or work.
2. Wandr books the appointment directly with the pharmacy on your behalf, including the chikungunya vaccine and any other travel vaccines you need.
3. You show up, the pharmacist administers the vaccine on-site. No separate doctor's visit, no calling pharmacies one by one to check stock.
4. Wandr handles the records. You leave with documentation that meets the standards required by international travel and yellow card programs.

Book your travel vaccines online at travelwithwandr.com.

Chikungunya vaccine for specific destinations

A short translation of the global outbreak data into practical recommendations for travelers heading to the destinations most US tourists actually visit.

Brazil

Brazil reported more chikungunya cases in 2024 than any prior year on record, with the northeast (Bahia, Pernambuco, Ceara) and Center-West regions hit hardest. The chikungunya vaccine is recommended for most travelers visiting Brazil in 2026, particularly if the itinerary involves time outside Sao Paulo and Rio. For more on Brazil-specific health planning, see our Brazil travel health guide.

India

Multiple Indian states have had ongoing chikungunya transmission through 2025 and into 2026. Vaccination is recommended for travelers spending more than a few days in India, especially in Maharashtra, Karnataka, Kerala, Tamil Nadu, and Delhi. See the India travel health guide for the full picture.

La Reunion and Indian Ocean

The 2024 to 2025 La Reunion outbreak was the largest single-country chikungunya epidemic in recent history. Vaccination is strongly recommended for any traveler to La Reunion, Mauritius, Seychelles, or Madagascar in 2026.

Caribbean

Periodic outbreaks have been reported in the Dominican Republic, Cuba, Trinidad, and Haiti. Vaccination is recommended if you are traveling to an island with an active outbreak at the time of your trip. CDC updates its destination-by-destination risk pages monthly.

Mexico, Central America, and Paraguay

Paraguay has seen the largest outbreak in this region in recent years. Mexico has periodic clusters, particularly along the Gulf Coast and Yucatan Peninsula. Vaccination is recommended if your itinerary includes regions with current transmission or if you are spending significant time outdoors.

Southeast Asia

Indonesia, Thailand, Cambodia, and the Philippines have all reported recent outbreaks. Vaccination is reasonable for travelers with longer itineraries or rural exposure.

Common mistakes I see travelers make with chikungunya prevention

After enough returning-traveler ER visits, the same patterns repeat. A few to avoid.

Mistake 1: Skipping the vaccine because "I have insect repellent." Repellent works, but only when applied correctly, every day, all day. Aedes mosquitoes bite during daylight hours, which is precisely when most people forget to reapply. Repellent plus vaccine is the right strategy in outbreak zones, not repellent alone.

Mistake 2: Booking the vaccine the week before departure. You need 14 days for immunity. Same-day vaccination at the airport does not work for chikungunya.

Mistake 3: Assuming dengue protection covers chikungunya. Dengvaxia and Qdenga protect against dengue, not chikungunya. The two viruses are spread by the same mosquito, but they are different pathogens and require different vaccines.

Mistake 4: Ignoring chronic joint pain after a recent trip. If you have new joint pain that started within 1 to 3 weeks of returning from a tropical destination, ask your physician about chikungunya serology. The acute infection often goes undiagnosed, and chronic arthritis can be confused with autoimmune disease.

Frequently asked questions

Do I really need the chikungunya vaccine if I am only going for a week?

If your one-week itinerary is in a city with active chikungunya transmission, the answer is usually yes, especially if you will be outdoors, in unscreened accommodations, or visiting friends and family. The acute infection can wreck the entire trip, and the chronic arthritis is what worries physicians most. A short trip is not a reason to skip the vaccine if your destination has active outbreaks.

Can I get the chikungunya vaccine if I have already had chikungunya?

Yes, vaccination is safe in people who have had chikungunya in the past, but it is generally not necessary. A previous infection produces durable immunity, and ACIP does not recommend routine vaccination of people with confirmed prior infection. If you are unsure whether a past illness was chikungunya, your physician can order a serology test.

Is the chikungunya vaccine safe during pregnancy?

Live-attenuated Ixchiq is generally avoided in pregnancy. Vimkunya, the virus-like particle vaccine, has limited pregnancy data and is not yet routinely recommended in pregnancy. If you are pregnant and traveling to a chikungunya outbreak area, talk to your obstetrician and a travel-medicine clinician about deferring travel or using strict mosquito-bite prevention measures instead.

How long does chikungunya vaccine immunity last?

Phase 3 clinical trials have demonstrated protective antibody levels lasting at least 2 to 3 years after a single dose of either Ixchiq or Vimkunya. Long-term follow-up studies are ongoing and may eventually support 5-year or longer durability. Currently, no booster dose is recommended.

Why is Ixchiq not recommended for adults over 65?

Post-marketing surveillance identified a small number of serious adverse events in older adults who received Ixchiq, including severe chikungunya-like illness and rare deaths in patients with significant comorbidities. The FDA added a precaution to the label in 2024, and ACIP now recommends Vimkunya as the preferred option in adults 65 and older when both vaccines are available.

Can children get the chikungunya vaccine?

Vimkunya is FDA-approved for ages 12 and older. Ixchiq is approved only for adults 18 and older. Children under 12 are not currently eligible for either vaccine, and prevention in that age group relies on insect-bite avoidance. Trials in younger pediatric populations are ongoing.

What is the difference between dengue and chikungunya?

Both are mosquito-borne viral illnesses spread by Aedes mosquitoes, but they are caused by different viruses and produce different symptoms. Dengue tends to cause higher fever, bleeding manifestations, and lower platelet counts. Chikungunya is dominated by severe joint pain that can persist for months. They require separate vaccines for prevention.

Can I get the chikungunya vaccine and yellow fever vaccine on the same day?

Current guidance generally supports same-day administration of chikungunya vaccine with other travel vaccines, including yellow fever, when timing requires it. Live vaccines may be co-administered or separated by 28 days; your clinician will plan the sequence based on your specific itinerary.

How quickly does chikungunya vaccine start working?

Both Ixchiq and Vimkunya produce protective antibody levels at approximately 14 days after vaccination. Plan to get vaccinated at least 2 weeks before departure. Ideal lead time is 4 to 6 weeks.

What if I cannot get vaccinated in time?

If you cannot get vaccinated at least 2 weeks before travel, the next-best strategy is rigorous mosquito-bite prevention: EPA-registered repellent (DEET 25 to 30%, picaridin 20%, or oil of lemon eucalyptus), permethrin-treated clothing, long sleeves and pants during peak biting hours, air conditioning or window screens, and bed nets if screens are unavailable. You may still benefit from vaccination if your trip is long enough that immunity will develop before exposure ends, but speak with a clinician.

Bottom line from a physician

Chikungunya is one of the few mosquito-borne illnesses where the chronic phase, not the acute infection, is what worries me most. Patients return from a Caribbean vacation feeling miserable for ten days, and then a third of them are still dealing with hand and knee pain six months later. With two single-dose vaccines now FDA-approved and a clear ACIP recommendation in place, the calculus for travelers heading to outbreak zones is straightforward. Get vaccinated at least 2 weeks before you travel. Pick Vimkunya if you are over 65, immunocompromised, or between 12 and 17. Either vaccine is reasonable for the rest of us.

If you are not sure whether your itinerary warrants chikungunya vaccination, the fastest way to find out is a pre-trip health check with a Wandr clinician. We will look at your exact destination, dates, and activities and tell you which vaccines and medications you actually need.

Book your travel vaccines online through Wandr and get your chikungunya shot at a partner pharmacy near you, often within a few days of booking.

Sources

• Centers for Disease Control and Prevention. "Chikungunya Virus." CDC Travelers' Health. cdc.gov/chikungunya
• US Food and Drug Administration. "Ixchiq Approval Letter." November 9, 2023. fda.gov
• US Food and Drug Administration. "Vimkunya Approval Letter." February 14, 2025. fda.gov
• Advisory Committee on Immunization Practices. "Use of Chikungunya Vaccines: Recommendations." MMWR Recommendations and Reports, 2024 and 2025 updates. cdc.gov/mmwr
• World Health Organization. "Chikungunya Fact Sheet." who.int/news-room/fact-sheets/detail/chikungunya
• Pan American Health Organization. "PLISA Health Information Platform — Chikungunya Cases in the Americas." paho.org
• Valneva SE. "Ixchiq US Prescribing Information." valneva.com
• Bavarian Nordic A/S. "Vimkunya US Prescribing Information." bavarian-nordic.com
• Schuffenecker I, et al. "Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak." PLOS Medicine.
• Suhrbier A. "Rheumatic manifestations of chikungunya: emerging concepts and interventions." Nature Reviews Rheumatology.

Medical disclaimer

This article is for informational purposes only and is not a substitute for personalized medical advice. Vaccine recommendations depend on your specific destination, dates of travel, medical history, and current outbreak status. Always consult a licensed clinician before making vaccination decisions. Wandr Health clinicians are available through our pre-trip health check at travelwithwandr.com.